LEADER 01250nam  2200289z- 450 
001 9910689511103321
005 20141104080545.0
035   $a(CKB)4100000011919570
035   $a(EXLCZ)994100000011919570
100   $a20210518c2003uuuu  -u-            -
101 0 $aeng
200 00$aBest-case series for the use of immuno-augmentation therapy and naltrexone for the treatment of cancer /$fprepared by Southern California-RAND Evidence-based Practice Center, Santa Monica, CA ; Ian Coulter, principle investigator ... [et al.]
210   $aRockville, MD : U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality
311   $a1-58763-082-6 
606   $aCancer$xTreatment
606   $aNaltrexone
615  0$aCancer$xTreatment.
615  0$aNaltrexone.
676   $a616.99/406
700   $aCoulter$b Ian D$01351450
701   $aHardy$b Mary L$01351451
712 02$aSouthern California Evidence-Based Practice Center/RAND.
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
906   $aBOOK
912   $a9910689511103321
996   $aBest-case series for the use of immuno-augmentation therapy and naltrexone for the treatment of cancer$93109023
997   $aUNINA